Kush Parmar's Net Worth
Estimate Recalculated Jun 18, 2025 08:33PM EST
Who is Kush Parmar
Kush Parmar does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Enliven Therapeutics, Inc., Skye Bioscience, Inc., , Entrada Therapeutics, Inc., Vor Biopharma Inc., Rallybio Corp, ARVINAS, INC., 5:01 Acquisition Corp., IMPEL NEUROPHARMA INC, scPharmaceuticals Inc., Cabaletta Bio, Inc., Akouos, Inc., Homology Medicines, Inc., Audentes Therapeutics, Inc., Aprea Therapeutics, Inc., and Artiva Biotherapeutics, Inc..
SEC CIK
Kush Parmar's CIK is 0001664281
Past Insider Trading and Trends
2022 was Kush Parmar's most active year for acquiring shares with 6 total transactions. Kush Parmar's most active month to acquire stocks was the month of May. 2019 was Kush Parmar's most active year for disposing of shares, totalling 1 transactions. Kush Parmar's most active month to dispose stocks was the month of August. 2024 saw Kush Parmar paying a total of $47,998.86 for 59,618 shares, this is the most they've acquired in one year. In 2022 Kush Parmar cashed out on 16,000 shares for a total of $0.00, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
